Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Delayed Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
94.86 USD +0.07% Intraday chart for Blueprint Medicines Corporation +5.34% +2.84%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing MT
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing MT
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety MT
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting CI
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO CI
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises MT
Transcript : Blueprint Medicines Corporation, Q4 2023 Earnings Call, Feb 15, 2024
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M MT
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024 CI
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating MT
Stifel Adjusts Blueprint Medicines' Price Target to $97 From $95, Keeps Buy Rating MT
Transcript : Blueprint Medicines Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 10:30 AM
Wedbush Lowers Blueprint Medicines' PT to $97 From $100 After Discussion of Strategic Priorities for 2024, Pipeline Update; Keeps Outperform Rating MT
Raymond James Adjusts Blueprint Medicines' Price Target to $100 From $85, Keeps Strong Buy Rating MT
Wells Fargo Raises Blueprint Medicines Price Target to $115 From $86, Maintains Overweight Rating MT
Blueprint Medicines Insider Sold Shares Worth $395,350, According to a Recent SEC Filing MT
Blueprint Medicines Receives European Approval for Ayvakyt in Indolent Systemic Mastocytosis MT
Blueprint Medicines' Ayvakyt (Avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis CI
Wedbush Raises Blueprint Medicines Price Target to $100 From $80, Maintains Outperform Rating MT
Blueprint Medicines Insider Sold Shares Worth $375,000, According to a Recent SEC Filing MT
Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted At 2023 Ash Annual Meeting CI
Chart Blueprint Medicines Corporation
More charts
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
94.86 USD
Average target price
97.38 USD
Spread / Average Target
+2.65%
Consensus